Compare Northrop Grumman Corporation (NOC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs GeneDx Holdings Corp — how do they compare? Northrop Grumman Corporation trades at $579 (market cap $81.78B), while GeneDx Holdings Corp trades at $82.28 (market cap $2.44B). The key difference: Northrop Grumman Corporation is far larger — about 33.5× GeneDx Holdings Corp's market cap, and Northrop Grumman Corporation pays a 1.63% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| NOC | WGS | |
|---|---|---|
Market Cap | $81.78B | $2.44B |
Sector | Industrials | Technology |
52-Week High | $768.02 | $167.51 |
52-Week Low | $496.02 | $34.51 |
Enterprise Value | $95.77B | $2.48B |
Dividend Yield | 1.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $577.12, down 0.13% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $7.68, and raised full-year guidance, supported by a record $105 billion backlog. Revenue growth is steady, with 2026 projected at $42.9 billion, and profitability remains solid with a net income margin of 10.48%.
The outlook is positive, driven by strategic contracts like the $7.6 billion Sentinel program and defense spending tailwinds. Risks include margin pressures from specific programs and geopolitical uncertainties. Analysts are bullish with a consensus price target of $598.57, suggesting upside potential from current levels.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
